Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Miromatrix Medical Inc.
Miromatrix Medical Inc. News
Dec 13, 2023 - businesswire.com
United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger
Dec 12, 2023 - businesswire.com
United Therapeutics and Miromatrix Medical Announce Successful Tender Offer
Nov 15, 2023 - businesswire.com
MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO
Nov 1, 2023 - businesswire.com
MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO
Miromatrix Medical Inc. Quantitative Score
About Miromatrix Medical Inc.
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
Miromatrix Medical Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Miromatrix Medical Inc. Financials
Table Compare
Compare MIRO metrics with: | |||
|---|---|---|---|
Earnings & Growth | MIRO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MIRO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MIRO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MIRO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Miromatrix Medical Inc. Income
Miromatrix Medical Inc. Balance Sheet
Miromatrix Medical Inc. Cash Flow
Miromatrix Medical Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Miromatrix Medical Inc. Executives
| Name | Role |
|---|---|
| Dr. Jeffrey James Ross Ph.D. | Chief Executive Officer & Director |
| Mr. James M. Douglas | Chief Financial Officer & Secretary |
| Mr. Brian D. Niebur CPA | Chief Financial Officer & Vice President of Fin. |
| Dr. John Joseph Barry Ph.D. | Vice President of R&D |
| Mr. Rodrigo Mesquita P.M.P. | Vice President of Manufacturing & Operations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Jeffrey James Ross Ph.D. | Chief Executive Officer & Director | 1976 | 797.5K | |
| Mr. James M. Douglas | Chief Financial Officer & Secretary | Male | 1974 | 487.5K |
| Mr. Brian D. Niebur CPA | Chief Financial Officer & Vice President of Fin. | Male | 1964 | 349.58K |
| Dr. John Joseph Barry Ph.D. | Vice President of R&D | -- | ||
| Mr. Rodrigo Mesquita P.M.P. | Vice President of Manufacturing & Operations | Male | -- |
Miromatrix Medical Inc. Insider Trades
| Date | 12 Dec |
| Name | UNITED THERAPEUTICS Corp |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 12 Dec |
| Name | Heine Lisa Wipperman |
| Role | Director |
| Transaction | Disposed |
| Type | U-Tender |
| Shares | 66943 |
| Date | 13 Dec |
| Name | Heine Lisa Wipperman |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 67413 |
| Date | 12 Dec |
| Name | Maag Peter |
| Role | Director |
| Transaction | Disposed |
| Type | U-Tender |
| Shares | 62092 |
| Date | 13 Dec |
| Name | Maag Peter |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 58368 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 12 Dec | UNITED THERAPEUTICS Corp | 10 percent owner | Disposed | 0 | |
| 12 Dec | Heine Lisa Wipperman | Director | Disposed | U-Tender | 66943 |
| 13 Dec | Heine Lisa Wipperman | Director | Disposed | D-Return | 67413 |
| 12 Dec | Maag Peter | Director | Disposed | U-Tender | 62092 |
| 13 Dec | Maag Peter | Director | Disposed | D-Return | 58368 |